AstraZeneca AB and AstraZeneca plc v European Commission (C-457/10 P)

Judgment of 6 Dec 2012

law://eu/cjeu/2010/c-457-10/para_58@2026-11-13

58Even if, contrary to what was held by the General Court, the Commission had committed a manifest error of assessment by taking into account the price of medicinal products over an identical period of treatment and, moreover, the general cost of PPI-based treatment, as the appellants claim, did not in actual fact exceed that of H2 blocker-based treatment, the fact remains that H2 blockers were not liable to exercise a significant competitive constraint over PPIs having regard, in particular, to the weight given by doctors and patients to the therapeutic superiority of PPIs.

AstraZeneca AB and AstraZeneca plc v European Commission (C-457/10 P)

Key facts

History · 1 version

Connections